OBSN.SW ObsEva (SIX) falls to CHF 0.0012 intraday 26 Feb 2026: volume spike
OBSN.SW stock dropped sharply intraday to CHF 0.0012 on 26 Feb 2026, down -76.92% as volume surged to 2,351,202 shares. The move left the stock well below its 50-day and 200-day averages, at CHF 0.01469 and CHF 0.04393 respectively. Traders flagged the large relative volume of 3.48x against an average of 675,842 as the key feature of today’s session on the SIX exchange in Switzerland. We break down where the price is, why liquidity matters, and how our Meyka AI model views next steps
OBSN.SW stock intraday snapshot
ObsEva S.A. (OBSN.SW) traded on the SIX exchange at CHF 0.0012 at the intraday low on 26 Feb 2026. The session range ran from a day low of CHF 0.0012 to a day high of CHF 0.0058. Previous close was CHF 0.00520 and the stock opened at CHF 0.00500. Market capitalisation is approximately CHF 140,612 with 117,177,000 shares outstanding. Volume today of 2,351,202 exceeded the average volume of 675,842, pushing relative volume to 3.48.
OBSN.SW stock drivers and news
There is no confirmed corporate press release tied to the intraday drop. In biotech names like ObsEva, price swings often follow clinical updates, licensing news, or funding announcements. ObsEva’s pipeline includes linzagolix (Phase III) and ebopiprant (Phase II); investors watch trial and partner updates closely. For official company information see the ObsEva website ObsEva.
OBSN.SW stock financials and valuation
ObsEva shows a small market cap and negative earnings profile. Trailing EPS is -0.29 and the PE ratio is negative. Key per-share measures: revenue per share 0.2133, book value per share 0.0921, and cash per share 0.09148. Price-to-sales is extremely low at about 0.01, reflecting the tiny market cap relative to recent sales. The company has a current ratio of 2.23, and debt-to-equity near 0.36, leaving short-term liquidity intact but growth funding uncertain.
OBSN.SW stock technicals and trading setup
Technically, the immediate support is the intraday low at CHF 0.0012. The first resistance is today’s high at CHF 0.0058, then the 50-day average near CHF 0.01469. Price averages show steep, downward momentum: 1-month change is -76.92% and 3-month change is -89.09%. High relative volume and wide intraday range create a volatile short-term trading environment suited to scalpers and momentum traders, not long-term buyers without additional news.
Meyka AI technical grade and analysis for OBSN.SW stock
Meyka AI rates OBSN.SW with a score out of 100: 62.66 giving a Grade B and a suggestion to HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The score reflects small market cap, negative EPS, reasonable short-term liquidity, and high volatility. These grades are not guarantees and we are not financial advisors.
OBSN.SW stock outlook, risks and catalysts
Catalysts that could move the stock include trial readouts, partner deals, or a financing announcement. Major risks include continued dilution, low liquidity, regulatory setbacks, and the company’s negative operating margins. Sector context: healthcare and biotech have shown mixed YTD performance; ObsEva sits in the Biotechnology industry where clinical binary events drive large moves. Watch shares outstanding and cash runway closely, as funding rounds can strongly re-price the stock.
Final Thoughts
Key takeaways for OBSN.SW stock: today’s intraday fall to CHF 0.0012 was accompanied by heavy trading, signalling fast re-pricing on limited float and low market cap. The company reports negative EPS and thin valuation metrics, with per-share cash of CHF 0.0915 offering some short-term liquidity cushion. Short-term traders should respect the intraday support at CHF 0.0012 and resistance at CHF 0.0058. Meyka AI’s forecast model projects a cautious base-case of CHF 0.0040 over a 12-month horizon, implying an upside of +233.33% versus the current price CHF 0.0012. Scenario planning matters: a downside scenario to CHF 0.0005 is possible if liquidity dries up, while a positive clinical or financing outcome could push the stock above CHF 0.0100. Forecasts are model-based projections and not guarantees. Use tight risk controls and monitor company announcements on the ObsEva site and regulatory channels. Meyka AI provides this AI-powered market analysis to help frame trading decisions, not to offer investment advice.
FAQs
Why did OBSN.SW stock fall so sharply today?
The intraday fall to CHF 0.0012 came with heavy volume. Biotech moves often follow clinical news, funding or liquidity events. No public company release matched the drop; low float and high relative volume amplified the decline.
What are the nearest technical levels for OBSN.SW stock?
Immediate support is the intraday low at CHF 0.0012. Near-term resistance is CHF 0.0058, then the 50-day average near CHF 0.01469. Use these levels for short-term trade planning.
How does Meyka AI rate OBSN.SW stock?
Meyka AI rates OBSN.SW with a score out of 100: 62.66, Grade B, suggestion HOLD. The grade factors in benchmark and sector comparisons, financial growth, key metrics, and analyst signals.
What is Meyka AI’s price forecast for OBSN.SW stock?
Meyka AI’s forecast model projects CHF 0.0040 over 12 months, implying +233.33% from CHF 0.0012. Forecasts are model-based projections and not guarantees.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.